Alpha-Synuclein (α-Synuclein)

Introduction

Alpha Synuclein (Α Synuclein) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

alpha-synuclein is a presynaptic neuronal protein central to a group of disorders collectively called synucleinopathies, including Parkinson’s disease, Lewy body dementia, ^{1Staging of brain pathology related to sporadic Parkinson's Disease (2003)2003 · PMID 12796765Open reference} and Multiple System Atrophy (MSA). Aggregated alpha-synuclein is a core component of Lewy bodies and Lewy neurites, placing it at the center of mechanistic models of selective ^{2Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice (2012)2012 · PMID 23161999Open reference} neuronal vulnerability and progressive network dysfunction^{3alpha-synuclein in filamentous inclusions of Lewy bodies from Parkinson's Disease and dementia with Lewy bodies (1998)1998 · PMID 9600990Open reference1Staging of brain pathology related to sporadic Parkinson's Disease (2003)2003 · PMID 12796765Open reference}. ^{4Parkinson's Disease, dementia with Lewy bodies, and Multiple System Atrophy as alpha-synucleinopathies (2017)2017 · PMID 28259760Open reference}

As a disease mechanism, alpha-synuclein biology spans protein misfolding, oligomerization, fibril growth, cell-to-cell propagation, and inflammatory response. Research over the ^{5alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro (2010)2010 · PMID 20395379Open reference} last decade has shifted from static inclusion-focused views toward dynamic models where strain-like conformers, cellular proteostasis capacity, and regional connectivity determine ^{6alpha-synuclein and dopamine at the crossroads of Parkinson's Disease (2010)2010 · PMID 20012576Open reference} progression trajectories^{2Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice (2012)2012 · PMID 23161999Open reference4Parkinson's Disease, dementia with Lewy bodies, and Multiple System Atrophy as alpha-synucleinopathies (2017)2017 · PMID 28259760Open reference}. ^{7Gaucher disease glucocerebrosidase and alpha-synuclein form a bidirectional pathogenic loop (2011)2011 · PMID 22078885Open reference}

Physiological Function and Protein Homeostasis

The SNCA gene encodes alpha-synuclein, a small intrinsically disordered protein enriched at presynaptic terminals. Under physiologic conditions, alpha-synuclein participates in synaptic vesicle cycling, membrane curvature sensing, and neurotransmitter release regulation. Its function depends on reversible transitions between soluble and membrane-associated conformations^{2Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice (2012)2012 · PMID 23161999Open reference}0^{2Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice (2012)2012 · PMID 23161999Open reference}1. ^{2Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice (2012)2012 · PMID 23161999Open reference}2

Cellular quality-control pathways, including chaperone systems, autophagy-lysosomal flux, and ubiquitin-proteasome activity, normally limit pathogenic accumulation. Disruption of these pathways by aging, genetic variants, mitochondrial stress, or neuroinflammation can increase the pool of misfolded and aggregation-prone species^{2Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice (2012)2012 · PMID 23161999Open reference}3^{2Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice (2012)2012 · PMID 23161999Open reference}4. ^{2Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice (2012)2012 · PMID 23161999Open reference}5

Aggregation, Strains, and Propagation

A key pathogenic step is the conversion of native alpha-synuclein into beta-sheet-rich oligomers and fibrils. Evidence from neuropathology and experimental systems indicates that ^{2Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice (2012)2012 · PMID 23161999Open reference}6 seeded aggregation can spread through anatomically connected circuits, consistent with progressive staging patterns observed in human disease^{2Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice (2012)2012 · PMID 23161999Open reference}7^{2Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice (2012)2012 · PMID 23161999Open reference}8. In vivo inoculation studies in mice demonstrated that exogenous fibrils can trigger endogenous alpha and downstream ^{2Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice (2012)2012 · PMID 23161999Open reference}9 dopaminergic injury^{3alpha-synuclein in filamentous inclusions of Lewy bodies from Parkinson's Disease and dementia with Lewy bodies (1998)1998 · PMID 9600990Open reference}0^{3alpha-synuclein in filamentous inclusions of Lewy bodies from Parkinson's Disease and dementia with Lewy bodies (1998)1998 · PMID 9600990Open reference}1. ^{3alpha-synuclein in filamentous inclusions of Lewy bodies from Parkinson's Disease and dementia with Lewy bodies (1998)1998 · PMID 9600990Open reference}2

Structural studies further support mechanistic heterogeneity. Different fibril conformations have been resolved by cryo-EM and solid-state approaches, including tissue-derived structures from Lewy body disorders. These conformational differences may help explain why synucleinopathies vary by cell type, clinical phenotype, and progression speed^{3alpha-synuclein in filamentous inclusions of Lewy bodies from Parkinson's Disease and dementia with Lewy bodies (1998)1998 · PMID 9600990Open reference}3^{3alpha-synuclein in filamentous inclusions of Lewy bodies from Parkinson's Disease and dementia with Lewy bodies (1998)1998 · PMID 9600990Open reference}4. ^{3alpha-synuclein in filamentous inclusions of Lewy bodies from Parkinson's Disease and dementia with Lewy bodies (1998)1998 · PMID 9600990Open reference}5

alpha-synuclein Across Synucleinopathies

Parkinson’s Disease

In Parkinson’s disease, alpha is tightly linked to degeneration of dopaminergic neurons in the substantia nigra and associated motor/non-motor syndromes. Genetic forms involving SNCA multiplications or missense variants provide strong causal evidence that increased burden or altered conformation of alpha-synuclein drives disease biology^{3alpha-synuclein in filamentous inclusions of Lewy bodies from Parkinson's Disease and dementia with Lewy bodies (1998)1998 · PMID 9600990Open reference}6^{3alpha-synuclein in filamentous inclusions of Lewy bodies from Parkinson's Disease and dementia with Lewy bodies (1998)1998 · PMID 9600990Open reference}7. ^{3alpha-synuclein in filamentous inclusions of Lewy bodies from Parkinson's Disease and dementia with Lewy bodies (1998)1998 · PMID 9600990Open reference}8

Dementia with Lewy bodies

In Lewy body dementia, widespread cortical and limbic alpha contributes to cognitive fluctuation, hallucinations, and attentional deficits. Co-pathology with Alzheimer’s disease features is common and can modify clinical expression^{3alpha-synuclein in filamentous inclusions of Lewy bodies from Parkinson's Disease and dementia with Lewy bodies (1998)1998 · PMID 9600990Open reference}9^{1Staging of brain pathology related to sporadic Parkinson's Disease (2003)2003 · PMID 12796765Open reference}0. ^{1Staging of brain pathology related to sporadic Parkinson's Disease (2003)2003 · PMID 12796765Open reference}1

Multiple System Atrophy

Multiple System Atrophy (MSA) features alpha-synuclein-rich glial cytoplasmic inclusions in oligodendroglial lineages, illustrating that the same protein can generate disease in distinct cellular contexts. This reinforces the idea of disease-specific conformers and microenvironmental determinants^{1Staging of brain pathology related to sporadic Parkinson's Disease (2003)2003 · PMID 12796765Open reference}2^{1Staging of brain pathology related to sporadic Parkinson's Disease (2003)2003 · PMID 12796765Open reference}3. ^{1Staging of brain pathology related to sporadic Parkinson's Disease (2003)2003 · PMID 12796765Open reference}4

Interactions with neuroinflammation and Cellular Stress

Misfolded alpha-synuclein is both a trigger and amplifier of innate immune signaling in microglia and astrocytes. Fibrillar and post-translationally modified alpha-synuclein species engage pattern-recognition pathways, drive cytokine release, and can sustain feed-forward injury loops that worsen synaptic and mitochondrial stress^{1Staging of brain pathology related to sporadic Parkinson's Disease (2003)2003 · PMID 12796765Open reference}5^{1Staging of brain pathology related to sporadic Parkinson's Disease (2003)2003 · PMID 12796765Open reference}6^{1Staging of brain pathology related to sporadic Parkinson's Disease (2003)2003 · PMID 12796765Open reference}7. ^{1Staging of brain pathology related to sporadic Parkinson's Disease (2003)2003 · PMID 12796765Open reference}8

Disease context matters: ^{1Staging of brain pathology related to sporadic Parkinson's Disease (2003)2003 · PMID 12796765Open reference}9

• Parkinson’s Disease: microglial activation frequently colocalizes with alpha-syn-rich regions and may shape progression kinetics via inflammasome and interferon-linked pathways.

• Dementia with Lewy bodies: post-mortem studies show neuroinflammatory burden that tracks with copathology and can modulate clinical expression, including cognitive fluctuation severity^{4Parkinson's Disease, dementia with Lewy bodies, and Multiple System Atrophy as alpha-synucleinopathies (2017)2017 · PMID 28259760Open reference}0^{4Parkinson's Disease, dementia with Lewy bodies, and Multiple System Atrophy as alpha-synucleinopathies (2017)2017 · PMID 28259760Open reference}1.

• Multiple System Atrophy: oligodendroglial alpha-syn inclusions are coupled to pronounced glial inflammatory responses, supporting a distinct glia-dominant inflammatory topology versus neuron-predominant synucleinopathies^{4Parkinson's Disease, dementia with Lewy bodies, and Multiple System Atrophy as alpha-synucleinopathies (2017)2017 · PMID 28259760Open reference}2.

These differences are therapeutically relevant: anti-inflammatory interventions likely need disease-specific stratification rather than a single pan-synucleinopathy regimen. ^{4Parkinson's Disease, dementia with Lewy bodies, and Multiple System Atrophy as alpha-synucleinopathies (2017)2017 · PMID 28259760Open reference}3

Cross-Disease Immune Mechanisms: PD, DLB, and MSA

Mechanistic overlap exists across Parkinson’s Disease, Lewy Body Dementia, and Multiple System Atrophy, but the dominant inflammatory context differs by cell-type involvement and aggregate compartmentalization. ^{4Parkinson's Disease, dementia with Lewy bodies, and Multiple System Atrophy as alpha-synucleinopathies (2017)2017 · PMID 28259760Open reference}4

• Parkinson’s Disease (PD): microglial activation is tightly linked to alpha-synuclein species burden and appears to amplify neuronal stress through inflammasome-linked cytokine signaling and phagocytic dysregulation^{4Parkinson's Disease, dementia with Lewy bodies, and Multiple System Atrophy as alpha-synucleinopathies (2017)2017 · PMID 28259760Open reference}5^{4Parkinson's Disease, dementia with Lewy bodies, and Multiple System Atrophy as alpha-synucleinopathies (2017)2017 · PMID 28259760Open reference}6^{4Parkinson's Disease, dementia with Lewy bodies, and Multiple System Atrophy as alpha-synucleinopathies (2017)2017 · PMID 28259760Open reference}7.

• Lewy Body Dementia (DLB): post-mortem and imaging-linked studies support a neuroinflammatory component that tracks with cortical network dysfunction and, in some cohorts, co-pathology burden^{4Parkinson's Disease, dementia with Lewy bodies, and Multiple System Atrophy as alpha-synucleinopathies (2017)2017 · PMID 28259760Open reference}8^{4Parkinson's Disease, dementia with Lewy bodies, and Multiple System Atrophy as alpha-synucleinopathies (2017)2017 · PMID 28259760Open reference}9.

• Multiple System Atrophy (MSA): oligodendroglial alpha-synucleinopathy creates a distinct glial injury niche where myelin-associated stress and innate immune activation can be disproportionate to neuronal Lewy-body-centric patterns^{5alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro (2010)2010 · PMID 20395379Open reference}0.

These differences matter for translational design: a biomarker or immune-targeting strategy that performs in PD may not transfer directly to DLB or MSA without disease-specific enrichment and endpoint calibration. ^{5alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro (2010)2010 · PMID 20395379Open reference}1

• Proteins/ATP13A2 - Lysosomal ATPase affecting alpha-synuclein clearance

• Proteins/FBXO7 - F-box protein in parkin-mediated mitophagy

• Proteins/CTSD - Lysosomal protease in alpha-synuclein degradation

Therapeutic Approaches

Multiple biotechnology companies are developing therapies targeting alpha-synuclein pathology:

Immunotherapies

• AC Immune — ACI-35 liposomal tau vaccine (also targets alpha-synuclein)

• Vaxxinity — VX15 alpha-synuclein vaccine

• Prothena — PRX002 (prasinezumab) anti-alpha-synuclein antibody

• UCB Pharma — UCB0599 alpha-synuclein misfolding inhibitor

Small Molecule Inhibitors

• Gain Therapeutics — GCase modulators targeting alpha-synuclein aggregation

• Denali Therapeutics — LRRK2 inhibitors may reduce alpha-synuclein phosphorylation

Gene Therapy

• Prevail Therapeutics — GBA1 gene therapy for PD (targets alpha-synuclein dysregulation)

See the PD Pipeline Companies index for clinical trial status and latest development updates.

Recent Research Updates (2024-2026)

Recent advances in alpha-synuclein research have revealed novel insights into structure, propagation mechanisms, and therapeutic targeting:

• Cryo-EM structures of alpha-synuclein filaments: High-resolution cryo-EM studies have identified novel filament subtypes in Multiple System Atrophy (MSA), revealing strain-specific structural differences that may explain the distinct clinical phenotypes of synucleinopathies^{5alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro (2010)2010 · PMID 20395379Open reference}2.

• RNA G-quadruplexes as aggregation scaffolds: Research demonstrates that RNA G-quadruplexes form scaffolds that promote neuropathological alpha-synuclein aggregation, providing new targets for therapeutic intervention in Parkinson’s disease^{5alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro (2010)2010 · PMID 20395379Open reference}3.

• alpha-Synuclein pathology as therapeutic target: Comprehensive reviews highlight emerging disease-modifying strategies targeting alpha-synuclein aggregation, including small molecule inhibitors, immunotherapy, and gene therapy approaches^{5alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro (2010)2010 · PMID 20395379Open reference}4.

• Gut-brain propagation pathways: Studies on gut-induced alpha-synuclein and tau propagation have revealed mechanisms by which peripheral pathology initiates neurodegeneration in the central nervous system, supporting the Braak hypothesis and identifying novel intervention points^{5alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro (2010)2010 · PMID 20395379Open reference}5.

• Immunotherapy clinical updates: Recent clinical trials of immune-based alpha-synuclein therapies have shown promise in modifying disease progression, with active and passive immunization strategies advancing through clinical development^{5alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro (2010)2010 · PMID 20395379Open reference}6.

• alpha-Synuclein biomarkers for Parkinson’s disease: A comprehensive 2026 review by Lodge and Agin-Liebes provides an updated overview of alpha-synuclein biomarkers including CSF and blood-based assays, PET ligands, and seeding assays (RT-QuIC, PMCA) for PD diagnosis and progression monitoring^{5alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro (2010)2010 · PMID 20395379Open reference}7.

• Glymphatic system targeting: Novel therapeutic strategies targeting the glymphatic system to promote alpha-synuclein clearance represent a promising new approach for PD treatment^{5alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro (2010)2010 · PMID 20395379Open reference}8.

See Also

• Parkinson’s disease - The primary disease associated with alpha

• Lewy body dementia - Another synucleinopathy characterized by Lewy bodies

• multiple system atrophy - A neurodegenerative synucleinopathy with oligodendroglial pathology

• Dementia with Lewy Bodies - Parkinsonism with cognitive fluctuations and visual hallucinations

• Synucleinopathies - Overview of diseases characterized by alpha

External Links

• UniProt: alpha-synuclein (P37840)

• OMIM: SNCA (163890)

• NCBI Gene: SNCA

• PDGene Database - Parkinson’s Disease genetic data

Visual Summary

Pathway Flowchart

flowchart TD
    NATIVE["Native Alpha-Synuclein\n(Soluble Monomer)"] -->|"Misfolding"| OLIGO["Oligomers\n(Toxic Intermediates)"]
    OLIGO -->|"Beta-Sheet\nConversion"| FIBRILS["Amyloid Fibrils"]
    FIBRILS --> LB["Lewy Bodies\nand Lewy Neurites"]
    OLIGO -->|"Membrane\nDisruption"| TOXICITY["Cellular Toxicity"]
    FIBRILS -->|"Cell-to-Cell\nTransmission"| SPREAD["Prion-like\nPropagation"]
    SPREAD --> STAGING["Braak Staging\nProgression"]
    NATIVE -.->|"SNCA Mutations\nor Triplication"| OLIGO
    OLIGO -->|"Impairs"| PROTEO["Proteostasis\n(UPS, Autophagy, CMA)"]
    PROTEO -.->|"Failure to\nClear"| OLIGO
    TOXICITY --> NEUROINF["Neuroinflammation\n(Microglial Activation)"]
    TOXICITY --> MITO["Mitochondrial\nDysfunction"]

SVG Diagram

!alpha-synuclein-aggregation pathway diagram ^{6alpha-synuclein and dopamine at the crossroads of Parkinson's Disease (2010)2010 · PMID 20012576Open reference}0

Figure: alpha synuclein aggregation pathway schematic generated for NeuroWiki. ^{6alpha-synuclein and dopamine at the crossroads of Parkinson's Disease (2010)2010 · PMID 20012576Open reference}1

Background

The study of Alpha Synuclein (Α Synuclein) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development. ^{6alpha-synuclein and dopamine at the crossroads of Parkinson's Disease (2010)2010 · PMID 20012576Open reference}2

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions. ^{6alpha-synuclein and dopamine at the crossroads of Parkinson's Disease (2010)2010 · PMID 20012576Open reference}3

Additional evidence sources: ^{6alpha-synuclein and dopamine at the crossroads of Parkinson's Disease (2010)2010 · PMID 20012576Open reference}4

Allen Brain Atlas Resources

• Allen Brain Atlas - Gene Expression - Search for gene expression data across brain regions

• Allen Brain Atlas - Cell Types - Explore neuronal cell type taxonomy

• Allen Brain Atlas - Aging, Dementia & TBI - Data on aging and traumatic brain injury

• BrainSpan Atlas of the Developing Human Brain - Developmental gene expression data

Confidence Assessment

🟡 Moderate Confidence

Overall Confidence: 44%